ASXC
Price
$0.24
Change
-$0.00 (-0.00%)
Updated
Apr 25, 6:59 PM EST
13 days until earnings call
CHEK
Price
$2.30
Change
+$0.08 (+3.60%)
Updated
Apr 25, 6:59 PM EST
19 days until earnings call
Ad is loading...

Compare trend and price ASXC vs CHEK

Header iconASXC vs CHEK Comparison
Open Charts ASXC vs CHEKBanner chart's image
Asensus Surgical
Price$0.24
Change-$0.00 (-0.00%)
Volume$705.83K
CapitalizationN/A
Check-Cap
Price$2.30
Change+$0.08 (+3.60%)
Volume$22.29K
CapitalizationN/A
View a ticker or compare two or three
ASXC vs CHEK Comparison Chart

Loading...

ASXCDaily Signal changed days agoGain/Loss if shorted
 
Show more...
CHEKDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
ASXC vs. CHEK commentary
Apr 26, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASXC is a Buy and CHEK is a Hold.

COMPARISON
Comparison
Apr 26, 2024
Stock price -- (ASXC: $0.24 vs. CHEK: $2.22)
Brand notoriety: ASXC and CHEK are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: ASXC: 60% vs. CHEK: 8%
Market capitalization -- ASXC: $59.84M vs. CHEK: $18.19M
ASXC [@Medical Specialties] is valued at $59.84M. CHEK’s [@Medical Specialties] market capitalization is $18.19M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.42B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASXC’s FA Score shows that 0 FA rating(s) are green whileCHEK’s FA Score has 1 green FA rating(s).

  • ASXC’s FA Score: 0 green, 5 red.
  • CHEK’s FA Score: 1 green, 4 red.
According to our system of comparison, CHEK is a better buy in the long-term than ASXC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ASXC’s TA Score shows that 4 TA indicator(s) are bullish while CHEK’s TA Score has 4 bullish TA indicator(s).

  • ASXC’s TA Score: 4 bullish, 5 bearish.
  • CHEK’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ASXC is a better buy in the short-term than CHEK.

Price Growth

ASXC (@Medical Specialties) experienced а -6.54% price change this week, while CHEK (@Medical Specialties) price change was +1.83% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +3.48%. For the same industry, the average monthly price growth was -0.49%, and the average quarterly price growth was +16.66%.

Reported Earning Dates

ASXC is expected to report earnings on Aug 07, 2024.

CHEK is expected to report earnings on Aug 01, 2024.

Industries' Descriptions

@Medical Specialties (+3.48% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
A.I.dvisor published
a Summary for ASXC with price predictions.
OPEN
A.I.dvisor published
a Summary for CHEK with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ASXC($59.8M) has a higher market cap than CHEK($18.2M). CHEK YTD gains are higher at: 6.731 vs. ASXC (-23.801). CHEK has higher annual earnings (EBITDA): -18.8M vs. ASXC (-74.39M). CHEK has more cash in the bank: 32.1M vs. ASXC (21.1M). CHEK has less debt than ASXC: CHEK (83K) vs ASXC (5.68M). ASXC has higher revenues than CHEK: ASXC (8.58M) vs CHEK (0).
ASXCCHEKASXC / CHEK
Capitalization59.8M18.2M329%
EBITDA-74.39M-18.8M396%
Gain YTD-23.8016.731-354%
P/E RatioN/AN/A-
Revenue8.58M0-
Total Cash21.1M32.1M66%
Total Debt5.68M83K6,846%
FUNDAMENTALS RATINGS
ASXC vs CHEK: Fundamental Ratings
ASXC
CHEK
OUTLOOK RATING
1..100
7833
VALUATION
overvalued / fair valued / undervalued
1..100
38
Fair valued
25
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
6347
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CHEK's Valuation (25) in the Medical Specialties industry is in the same range as ASXC (38) in the Miscellaneous Commercial Services industry. This means that CHEK’s stock grew similarly to ASXC’s over the last 12 months.

CHEK's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ASXC (100) in the Miscellaneous Commercial Services industry. This means that CHEK’s stock grew similarly to ASXC’s over the last 12 months.

CHEK's SMR Rating (97) in the Medical Specialties industry is in the same range as ASXC (99) in the Miscellaneous Commercial Services industry. This means that CHEK’s stock grew similarly to ASXC’s over the last 12 months.

CHEK's Price Growth Rating (47) in the Medical Specialties industry is in the same range as ASXC (63) in the Miscellaneous Commercial Services industry. This means that CHEK’s stock grew similarly to ASXC’s over the last 12 months.

CHEK's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as ASXC (100) in the Miscellaneous Commercial Services industry. This means that CHEK’s stock grew similarly to ASXC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ASXCCHEK
RSI
ODDS (%)
Bullish Trend 2 days ago
68%
Bearish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 16 days ago
81%
Bullish Trend 29 days ago
81%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 11 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
ASXCDaily Signal changed days agoGain/Loss if shorted
 
Show more...
CHEKDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AIRG5.620.05
+0.90%
Airgain
BKNG3517.52-16.47
-0.47%
Booking Holdings
GLP46.68-0.27
-0.58%
Global Partners LP
UGP5.04-0.09
-1.75%
Ultrapar Participacoes SA
BMEA10.77-0.21
-1.91%
Biomea Fusion

ASXC and

Correlation & Price change

A.I.dvisor indicates that over the last year, ASXC has been loosely correlated with RVTY. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ASXC jumps, then RVTY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASXC
1D Price
Change %
ASXC100%
-2.41%
RVTY - ASXC
36%
Loosely correlated
-0.79%
EW - ASXC
30%
Poorly correlated
+0.98%
ITGR - ASXC
29%
Poorly correlated
+4.55%
BNGO - ASXC
29%
Poorly correlated
-4.19%
ALGN - ASXC
29%
Poorly correlated
+0.61%
More

CHEK and

Correlation & Price change

A.I.dvisor tells us that CHEK and TWST have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CHEK and TWST's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHEK
1D Price
Change %
CHEK100%
-3.06%
TWST - CHEK
26%
Poorly correlated
-2.38%
RSLS - CHEK
26%
Poorly correlated
-1.41%
SENS - CHEK
25%
Poorly correlated
+0.70%
WRBY - CHEK
25%
Poorly correlated
-2.39%
NEO - CHEK
24%
Poorly correlated
-0.92%
More